Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 181)
Posted On: 04/05/2019 3:46:48 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Talks DehydraTECH’s Lifesaving Technology on CEO Clips
- LXRP CEO Chris Bunka explained in the interview that proprietary technology can save 60,000 lives annually if consumption habits of even one percent of smokers worldwide change
- CEO Clips videos are featured on business sites including BNN Bloomberg, Thomson Reuters, Yahoo! Finance and Stockhouse.com
- Bunka went on to described LXRP’s growing patent portfolio and noted that ingesting rather than inhaling, using DehydraTECH technology, could be a lifesaver
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka sought to raise awareness of LXRP in the financial community as he appeared, March 23-24, on CEO Clips via YouTube. In the video, Bunka explained the benefits of DehydraTECH technology, noting that ingesting drugs and molecules is healthier than inhaling them, and doing so could be a lifesaver for smokers around the world.
CEO Clips boasts the largest library of publicly traded CEO videos broadcast in the United States and Canada on national TV and on 15 business sites, such as BNN Bloomberg, Yahoo! Finance, Thomson Reuters, Stockhouse.com and others.
“Lexaria Bioscience has the actual opportunity of changing the world,” Bunka said in the video (http://nnw.fm/P9i7W). “We can do it through saving lives, making health improvements for any number of people who are injecting any number of drugs or molecules like pain relief, cannabinoids or nicotine. Everybody knows that smoking is not healthy. Our technology allows for the delivery of drug molecules like cannabinoids or nicotine through ingestible means, things that you swallow. It could be a pill, a syrup or a cup of coffee. That technology, which is called DehydraTECH, is optimized to carry that drug across the intestinal wall and get more of it to your bloodstream more quickly than it otherwise could.”
He added that LXRP has tested DehydraTECH in vitro and in vivo in human clinical studies. Bunka further explained, “We actually have seven different R&D projects that we are launching in the first half of 2019. We’re also continuing to work on our patent portfolio. We have ten patents granted already and over 50 more that are pending. If we are able to help change the consumption habits of even one percent of the global marketplace who smoke we could save 60,000 lives a year.”
Based in British Columbia, Canada, LXRP is a biotechnology company and drug-delivery platform innovator, and DehydraTECH is the company’s proprietary absorption technology platform. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio that includes 10 patents granted in the United States and Australia, and more than 50 patent applications worldwide across 10 patent families.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- LXRP CEO Chris Bunka explained in the interview that proprietary technology can save 60,000 lives annually if consumption habits of even one percent of smokers worldwide change
- CEO Clips videos are featured on business sites including BNN Bloomberg, Thomson Reuters, Yahoo! Finance and Stockhouse.com
- Bunka went on to described LXRP’s growing patent portfolio and noted that ingesting rather than inhaling, using DehydraTECH technology, could be a lifesaver
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka sought to raise awareness of LXRP in the financial community as he appeared, March 23-24, on CEO Clips via YouTube. In the video, Bunka explained the benefits of DehydraTECH technology, noting that ingesting drugs and molecules is healthier than inhaling them, and doing so could be a lifesaver for smokers around the world.
CEO Clips boasts the largest library of publicly traded CEO videos broadcast in the United States and Canada on national TV and on 15 business sites, such as BNN Bloomberg, Yahoo! Finance, Thomson Reuters, Stockhouse.com and others.
“Lexaria Bioscience has the actual opportunity of changing the world,” Bunka said in the video (http://nnw.fm/P9i7W). “We can do it through saving lives, making health improvements for any number of people who are injecting any number of drugs or molecules like pain relief, cannabinoids or nicotine. Everybody knows that smoking is not healthy. Our technology allows for the delivery of drug molecules like cannabinoids or nicotine through ingestible means, things that you swallow. It could be a pill, a syrup or a cup of coffee. That technology, which is called DehydraTECH, is optimized to carry that drug across the intestinal wall and get more of it to your bloodstream more quickly than it otherwise could.”
He added that LXRP has tested DehydraTECH in vitro and in vivo in human clinical studies. Bunka further explained, “We actually have seven different R&D projects that we are launching in the first half of 2019. We’re also continuing to work on our patent portfolio. We have ten patents granted already and over 50 more that are pending. If we are able to help change the consumption habits of even one percent of the global marketplace who smoke we could save 60,000 lives a year.”
Based in British Columbia, Canada, LXRP is a biotechnology company and drug-delivery platform innovator, and DehydraTECH is the company’s proprietary absorption technology platform. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio that includes 10 patents granted in the United States and Australia, and more than 50 patent applications worldwide across 10 patent families.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼